CYPHERPUNK TECHNOLOGIES INC. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of 3.90% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2022-03-11
- CYPHERPUNK TECHNOLOGIES INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 3.90%, a 35.00% decline from fiscal 2020.
- CYPHERPUNK TECHNOLOGIES INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2020 was 6.00%, a 81.82% increase from fiscal 2019.
- CYPHERPUNK TECHNOLOGIES INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2019 was 3.30%, a 52.45% decline from fiscal 2018.
- CYPHERPUNK TECHNOLOGIES INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2018 was 6.94%, a 101.16% increase from fiscal 2017.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2021-12-31 | 3.90% 10-K · filed 2022-03-11 | |
| 2020-12-31 | 6.00% 10-K · filed 2022-03-11 | 5.98% 10-K · filed 2021-03-12 |
| 2019-12-31 | 3.30% 10-K · filed 2021-03-12 | |
| 2018-12-31 | 6.94% 10-K · filed 2020-03-16 | |
| 2017-12-31 | 3.45% 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |